Wiep Klaas Smits (ExpBac/CMAT)
@smitslab.bsky.social
Assoc. prof. at LUMC/@unileiden. Cdiff, DNA replication, AMR, microbiome, anaerobes. Clostpath Steering committee. Education officer ESGCD. Previously: @unigroningen and @mitofficial. https://sites.google.com/view/expbac-lumc/homepage
Time to look at PolC inhibitors :) bsky.app/profile/smit...
🚨 Publication alert! We are stoked to report the structural basis for activity of a novel class of antimicrobials targeting Gram positive priority pathogens in @natcomms.nature.com. There is something for everyone on this paper, and I will highlight a few things below 👇 1/9 doi.org/10.1038/s414...
A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens - Nature Communications
In this work, Urem et al. characterize the mode of action as well as mechanism of reduced susceptibility related to a class of antimicrobials that is in development for the treatment of infections wit...
doi.org
November 8, 2025 at 11:07 PM
Time to look at PolC inhibitors :) bsky.app/profile/smit...
Thanks, Stephan!
November 6, 2025 at 11:38 AM
Thanks, Stephan!
Finally; the work was funded in part by Health~Holland (www.health-holland.com), and made possible by the amazing facilities at the LUMC_Leiden and NeCEN (www.necen.nl), and our collaborator Meindert Lamers. 9/9
Health~Holland
Top Sector LSH initiates and stimulates interdisciplinary R&D in public private partnerships. By attracting funding, sharing best practices and the univocal sector communication, the Top Sector wants ...
www.health-holland.com
November 6, 2025 at 10:35 AM
Finally; the work was funded in part by Health~Holland (www.health-holland.com), and made possible by the amazing facilities at the LUMC_Leiden and NeCEN (www.necen.nl), and our collaborator Meindert Lamers. 9/9
We can now understand mechanism of action, as well as resistance of this class of compounds. Hopefully this will pave the way for even better PolC inhibitors and a successful treatment for CDI (IBZ entering Phase 3 now) and other infections. Nice to have this out in #cdiffawarenessmonth. 8/9
November 6, 2025 at 10:34 AM
We can now understand mechanism of action, as well as resistance of this class of compounds. Hopefully this will pave the way for even better PolC inhibitors and a successful treatment for CDI (IBZ entering Phase 3 now) and other infections. Nice to have this out in #cdiffawarenessmonth. 8/9